Exemestane Tablet
FDA Label NDC 0832-0595

32 label sections · Submitted to the FDA by Upsher-smith Laboratories, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Upsher-smith Laboratories, Inc. for the product Exemestane (NDC 0832-0595). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 adjuvant treatment of postmenopausal women, 1.2 advanced breast cancer in postmenopausal women, 2.1 recommended dose, 2.2 dose modifications, 3 dosage forms and strengths, 4 contraindications, 5.1 reductions in bone mineral density (bmd), 5.2 vitamin d assessment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

1.1 Adjuvant Treatment Of Postmenopausal Women

Exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1)].

1.2 Advanced Breast Cancer In Postmenopausal Women

Exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2)].

The recommended dose of exemestane tablets in early and advanced breast cancer is one 25 mg tablet once daily after a meal.

  • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy.
  • the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

2.2 Dose Modifications

Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. For patients receiving exemestane tablets with a strong CYP 3A4 inducer such as rifampicin or phenytoin, the recommended dose of exemestane tablets is 50 mg once daily after a meal [see Drug Interactions (7)and Clinical Pharmacology (12.3)].

3 Dosage Forms And Strengths

Exemestane tablets are a white to off-white, round, biconvex, bevel-edged, film-coated tablet engraved with 'US' on one face and plain on the other.

4 Contraindications

Exemestane is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.

5.1 Reductions In Bone Mineral Density (Bmd)

Reductions in bone mineral density (BMD) over time are seen with exemestane use. Table 1 describes changes in BMD from baseline to 24 months in patients receiving exemestane compared to patients receiving tamoxifen (IES) or placebo (027). Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed.

Table 1. Percent Change in BMD from Baseline to 24 months, Exemestane vs. Control 1
IES027
BMDExemestane
N=29
Tamoxifen 1
N=38
Exemestane
N=59
Placebo 1
N=65
Lumbar spine (%)-3.1-0.2-3.5-2.4
Femoral neck (%)-4.2-0.3-4.6-2.6

During adjuvant treatment with exemestane, women with osteoporosis or at risk of osteoporosis should have their bone mineral density formally assessed by bone densitometry at the commencement of treatment. Monitor patients for bone mineral density loss and treat as appropriate.

5.2 Vitamin D Assessment

Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed, due to the high prevalence of vitamin D deficiency in women with early breast cancer (EBC). Women with vitamin D deficiency should receive supplementation with vitamin D.

5.3 Administration With Estrogen-Containing Agents

Exemestane should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action.

5.4 Laboratory Abnormalities

In patients with early breast cancer, the incidence of hematological abnormalities of Common Toxicity Criteria (CTC) grade ≥1 was lower in the exemestane treatment group, compared with tamoxifen. Incidence of CTC grade 3 or 4 abnormalities was low (approximately 0.1%) in both treatment groups. Approximately 20% of patients receiving exemestane in clinical studies in advanced breast cancer experienced CTC grade 3 or 4 lymphocytopenia. Of these patients, 89% had a pre-existing lower grade lymphopenia. Forty percent of patients either recovered or improved to a lesser severity while on treatment. Patients did not have a significant increase in viral infections, and no opportunistic infections were observed. Elevations of serum levels of AST, ALT, alkaline phosphatase, and gamma glutamyl transferase >5 times the upper value of the normal range (i.e., ≥ CTC grade 3) have been rarely reported in patients treated for advanced breast cancer but appear mostly attributable to the underlying presence of liver and/or bone metastases. In the comparative study in advanced breast cancer patients, CTC grade 3 or 4 elevation of gamma glutamyl transferase without documented evidence of liver metastasis was reported in 2.7% of patients treated with exemestane and in 1.8% of patients treated with megestrol acetate.

In patients with early breast cancer, elevations in bilirubin, alkaline phosphatase, and creatinine were more common in those receiving exemestane than either tamoxifen or placebo. Treatment-emergent bilirubin elevations (any CTC grade) occurred in 5% of exemestane patients and 0.8% of tamoxifen patients on the Intergroup Exemestane Study (IES), and in 7% of exemestane treated patients vs. 0% of placebo treated patients in the 027 study. CTC grade 3 to 4 increases in bilirubin occurred in 0.9% of exemestane treated patients compared to 0.1% of tamoxifen treated patients. Alkaline phosphatase elevations of any CTC grade occurred in 15% of exemestane treated patients on the IES compared to 2.6% of tamoxifen treated patients, and in 14% of exemestane treated patients compared to 7% of placebo treated patients in study 027. Creatinine elevations occurred in 6% of exemestane treated patients and 4.3% of tamoxifen treated patients on the IES and in 6% of exemestane treated patients and 0% of placebo treated patients in study 027.

5.5 Use In Premenopausal Women

Exemestane is not indicated for the treatment of breast cancer in premenopausal women.

5.6 Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abortions and embryo-fetal toxicity. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with exemestane and for 1 month after the last dose [see Use in Specific Populations (8.1), (8.3)and Clinical Pharmacology (12.1)].

6 Adverse Reactions

The following clinically significant adverse reactions are described elsewhere in the labeling:

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

6.2 Post-Marketing Experience

The following adverse reactions have been identified during post approval use of exemestane. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune system disorders– hypersensitivity

Hepatobiliary disorders– hepatitis including cholestatic hepatitis

Nervous system disorders– paresthesia

Musculoskeletal and connective tissue disorder– tendon disorders including tendon rupture, tendonitis, and tenosynovitis

Skin and subcutaneous tissue disorders– acute generalized exanthematous pustulosis, urticaria, pruritus

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.6 Hepatic Impairment

The AUC of exemestane was increased in subjects with moderate or severe hepatic impairment (Childs-Pugh B or C) [see Clinical Pharmacology (12.3)]. However, based on experience with exemestane at repeated doses up to 200 mg daily that demonstrated a moderate increase in non-life-threatening adverse reactions, dosage adjustment does not appear to be necessary.

8.7 Renal Impairment

The AUC of exemestane was increased in subjects with moderate or severe renal impairment (creatinine clearance <35 mL/min/1.73 m 2) [see Clinical Pharmacology (12.3)]. However, based on experience with exemestane at repeated doses up to 200 mg daily that demonstrated a moderate increase in non-life-threatening adverse reactions, dosage adjustment does not appear to be necessary.

10 Overdosage

Clinical trials have been conducted with exemestane given as a single dose to healthy female volunteers at doses as high as 800 mg and daily for 12 weeks to postmenopausal women with advanced breast cancer at doses as high as 600 mg. These dosages were well tolerated. There is no specific antidote to overdosage and treatment must be symptomatic. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.

A male child (age unknown) accidentally ingested a 25 mg tablet of exemestane. The initial physical examination was normal, but blood tests performed 1 hour after ingestion indicated leucocytosis (WBC 25,000/mm 3with 90% neutrophils). Blood tests were repeated 4 days after the incident and were normal. No treatment was given.

In mice, mortality was observed after a single oral dose of exemestane of 3,200 mg/kg, the lowest dose tested (about 640 times the recommended human dose on a mg/m 2basis). In rats and dogs, mortality was observed after single oral doses of exemestane of 5,000 mg/kg (about 2,000 times the recommended human dose on a mg/m 2basis) and of 3,000 mg/kg (about 4,000 times the recommended human dose on a mg/m 2basis), respectively.

Convulsions were observed after single doses of exemestane of 400 mg/kg and 3,000 mg/kg in mice and dogs (approximately 80 and 4,000 times the recommended human dose on a mg/m 2basis), respectively.

11 Description

Exemestane tablets, USP for oral administration contain 25 mg of exemestane, an irreversible, steroidal aromatase inactivator. Exemestane, USP is chemically described as 6-methylenandrosta-1,4-diene-3,17-dione. Its molecular formula is C 20H 24O 2and its structural formula is as follows:

Chemical Structure (Exemestane 01)

Chemical Structure (Exemestane 01)

The active ingredient is a white to slightly yellow crystalline powder with a molecular weight of 296.41. Exemestane is freely soluble in N, N-dimethylformamide, soluble in methanol, and practically insoluble in water.

Each exemestane tablet contains the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide.

FDA approved dissolution test specifications differs from USP.

12.1 Mechanism Of Action

Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues.

Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme, causing its inactivation, an effect also known as "suicide inhibition". Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.

12.3 Pharmacokinetics

Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours. The pharmacokinetics of exemestane are dose proportional after single (10 to 200 mg) or repeated oral doses (0.5 to 50 mg). Following repeated daily doses of exemestane 25 mg, plasma concentrations of unchanged drug are similar to levels measured after a single dose. Pharmacokinetic parameters in postmenopausal women with advanced breast cancer following single or repeated doses have been compared with those in healthy, postmenopausal women. After repeated dosing, the average oral clearance in women with advanced breast cancer was 45% lower than the oral clearance in healthy postmenopausal women, with corresponding higher systemic exposure. Mean AUC values following repeated doses in women with breast cancer (75.4 ng∙h/mL) were about twice those in healthy women (41.4 ng∙h/mL).

Drug Interactions

Drug Interaction Studies

Exemestane does not inhibit any of the major CYP isoenzymes, including CYP 1A2, 2C9, 2D6, 2E1, and 3A4.

In a pharmacokinetic interaction study of 10 healthy postmenopausal volunteers pretreated with potent CYP 3A4 inducer rifampicin 600 mg daily for 14 days followed by a single dose of exemestane 25 mg, the mean plasma C maxand AUC 0–∞of exemestane were decreased by 41% and 54%, respectively [see Dosage and Administration (2.2)and Drug Interactions (7)].

In a clinical pharmacokinetic study, coadministration of ketoconazole, a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics. Although no other formal drug-drug interaction studies with inhibitors have been conducted, significant effects on exemestane clearance by CYP isoenzyme inhibitors appear unlikely.

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

A 2-year carcinogenicity study in mice at doses of 50, 150, and 450 mg/kg/day exemestane (gavage), resulted in an increased incidence of hepatocellular adenomas and/or carcinomas in both genders at the high dose level. Plasma AUC (0–24hr)at the high dose were 2,575 ± 386 and 5,667 ± 1,833 ng∙hr/mL in males and females (approx. 34 and 75 fold the AUC in postmenopausal patients at the recommended clinical dose). An increased incidence of renal tubular adenomas was observed in male mice at the high dose of 450 mg/kg/day. Since the doses tested in mice did not achieve an MTD, neoplastic findings in organs other than liver and kidneys remain unknown.

A separate carcinogenicity study was conducted in rats at the doses of 30, 100, and 315 mg/kg/day exemestane (gavage) for 92 weeks in males and 2 years in females. No evidence of carcinogenic activity up to the highest dose tested of 315 mg/kg/day was observed in females. The male rat study was inconclusive since it was terminated prematurely at Week 92. At the highest dose, plasma AUC (0–24hr)levels in male (1,418 ± 287 ng∙hr/mL) and female (2,318 ± 1,067 ng∙hr/mL) rats were 19 and 31 fold higher than those measured in postmenopausal cancer patients receiving the recommended clinical dose.

Exemestane was not mutagenic in vitroin bacteria (Ames test) or mammalian cells (V79 Chinese hamster lung cells). Exemestane was clastogenic in human lymphocytes in vitrowithout metabolic activation but was not clastogenic in vivo(micronucleus assay in mouse bone marrow). Exemestane did not increase unscheduled DNA synthesis in rat hepatocytes when tested in vitro.

In a pilot reproductive study in rats, male rats were treated with doses of 125 to 1,000 mg/kg/day exemestane, beginning 63 days prior to and during cohabitation. Untreated female rats showed reduced fertility when mated to males treated with ≥500 mg/kg/day exemestane (≥200 times the recommended human dose on a mg/m 2basis). In a separate study, exemestane was given to female rats at 4 to 100 mg/kg/day beginning 14 days prior to mating and through day 15 or 20 of gestation. Exemestane increased the placental weights at ≥4 mg/kg/day (≥1.5 times the human dose on a mg/m 2basis). Exemestane showed no effects on ovarian function, mating behavior, and conception rate in rats given doses up to 20 mg/kg/day (approximately 8 times the recommended human dose on a mg/m 2basis); however, decreases in mean litter size and fetal body weight, along with delayed ossification were evidenced at ≥20 mg/kg/day. In general toxicology studies, changes in the ovary, including hyperplasia, an increase in the incidence of ovarian cysts, and a decrease in corpora lutea were observed with variable frequency in mice, rats, and dogs at doses that ranged from 3 to 20 times the human dose on a mg/m 2basis.

14.1 Adjuvant Treatment In Early Breast Cancer

The Intergroup Exemestane Study 031 (IES) was a randomized, double-blind, multicenter, multinational study comparing exemestane (25 mg/day) vs. tamoxifen (20 or 30 mg/day) in postmenopausal women with early breast cancer. Patients who remained disease-free after receiving adjuvant tamoxifen therapy for 2 to 3 years were randomized to receive an additional 3 or 2 years of exemestane or tamoxifen to complete a total of 5 years of hormonal therapy.

The primary objective of the study was to determine whether, in terms of disease-free survival, it was more effective to switch to exemestane rather than continuing tamoxifen therapy for the remainder of five years. Disease-free survival was defined as the time from randomization to time of local or distant recurrence of breast cancer, contralateral invasive breast cancer, or death from any cause.

The secondary objectives were to compare the two regimens in terms of overall survival and long-term tolerability. Time to contralateral invasive breast cancer and distant recurrence-free survival were also evaluated.

A total of 4,724 patients in the intent-to-treat (ITT) analysis were randomized to exemestane tablets 25 mg once daily (N = 2,352) or to continue to receive tamoxifen once daily at the same dose received before randomization (N = 2,372). Demographics and baseline tumor characteristics are presented in Table 5. Prior breast cancer therapy is summarized in Table 6.

Table 5. Demographic and Baseline Tumor Characteristics from the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)
ParameterExemestane
(N = 2,352)
Tamoxifen
(N = 2,372)
Age (years):
Median age (range)63.0 (38.0 – 96.0)63.0 (31.0 – 90.0)
Race, n (%):
Caucasian2,315 (98.4)2,333 (98.4)
Hispanic13 (0.6)13 (0.5)
Asian10 (0.4)9 (0.4)
Black7 (0.3)10 (0.4)
Other/not reported7 (0.3)7 (0.3)
Nodal status, n (%):
Negative1,217 (51.7)1,228 (51.8)
Positive1,051 (44.7)1,044 (44.0)
  1–3 Positive nodes721 (30.7)708 (29.8)
  4–9 Positive nodes239 (10.2)244 (10.3)
  >9 Positive nodes88 (3.7)86 (3.6)
  Not reported3 (0.1)6 (0.3)
Unknown or missing84 (3.6)100 (4.2)
Histologic type, n (%):
Infiltrating ductal1,777 (75.6)1,830 (77.2)
Infiltrating lobular341 (14.5)321 (13.5)
Other231 (9.8)213 (9.0)
Unknown or missing3 (0.1)8 (0.3)
Receptor status

Results for receptor status include the results of the post-randomization testing of specimens from subjects for whom receptor status was unknown at randomization.

, n (%):
ER and PgR Positive1,331 (56.6)1,319 (55.6)
ER Positive and PgR Negative/Unknown677 (28.8)692 (29.2)
ER Unknown and PgR Positive

Only one subject in the exemestane group had unknown ER status and positive PgR status.

/Unknown
288 (12.2)291 (12.3)
ER Negative and PgR Positive6 (0.3)7 (0.3)
ER Negative and PgR Negative/Unknown (none positive)48 (2.0)58 (2.4)
Missing2 (0.1)5 (0.2)
Tumor Size, n (%):
≤ 0.5 cm58 (2.5)46 (1.9)
> 0.5 – 1.0 cm315 (13.4)302 (12.7)
> 1.0 – 2 cm1,031 (43.8)1,033 (43.5)
> 2.0 – 5.0 cm833 (35.4)883 (37.2)
> 5.0 cm62 (2.6)59 (2.5)
Not reported53 (2.3)49 (2.1)
Tumor Grade, n (%):
G1397 (16.9)393 (16.6)
G2977 (41.5)1,007 (42.5)
G3454 (19.3)428 (18.0)
G423 (1.0)19 (0.8)
Unknown/Not Assessed/Not reported501 (21.3)525 (22.1)
Table 6. Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)
ParameterExemestane
(N = 2,352)
Tamoxifen
(N = 2,372)
Type of surgery, n (%):
Mastectomy1,232 (52.4)1,242 (52.4)
Breast-conserving1,116 (47.4)1,123 (47.3)
Unknown or missing4 (0.2)7 (0.3)
Radiotherapy to the breast, n (%):
Yes1,524 (64.8)1,523 (64.2)
No824 (35.5)843 (35.5)
Not reported4 (0.2)6 (0.3)
Prior therapy, n (%):
Chemotherapy774 (32.9)769 (32.4)
Hormone replacement therapy567 (24.1)561 (23.7)
Bisphosphonates43 (1.8)34 (1.4)
Duration of tamoxifen therapy at randomization (months):
Median (range)28.5 (15.8 – 52.2)28.4 (15.6 – 63.0)
Tamoxifen dose, n (%):
20 mg2,270 (96.5)2,287 (96.4)
30 mg

The 30 mg dose was used only in Denmark, where this dose was the standard of care.

78 (3.3)75 (3.2)
Not reported4 (0.2)10 (0.4)

After a median duration of therapy of 27 months and with a median follow-up of 34.5 months, 520 events were reported, 213 in the exemestane group and 307 in the tamoxifen group (Table 7).

Table 7. Primary Endpoint Events (ITT Population)
EventFirst Events
N (%)
Exemestane
(N = 2,352)
Tamoxifen
(N = 2,372)
Loco-regional recurrence34 (1.45)45 (1.90)
Distant recurrence126 (5.36)183 (7.72)
Second primary – contralateral breast cancer7 (0.30)25 (1.05)
Death – breast cancer1 (0.04)6 (0.25)
Death – other reason41 (1.74)43 (1.81)
Death – missing/unknown3 (0.13)5 (0.21)
Ipsilateral breast cancer1 (0.04)0
Total number of events213 (9.06)307 (12.94)

Disease-free survival in the intent-to-treat population was statistically significantly improved [Hazard Ratio (HR) = 0.69, 95% CI: 0.58, 0.82, P = 0.00003, Table 8, Figure 1] in the exemestane arm compared to the tamoxifen arm. In the hormone receptor-positive subpopulation representing about 85% of the trial patients, disease-free survival was also statistically significantly improved (HR = 0.65, 95% CI: 0.53, 0.79, P = 0.00001) in the exemestane arm compared to the tamoxifen arm. Consistent results were observed in the subgroups of patients with node negative or positive disease, and patients who had or had not received prior chemotherapy.

An overall survival update at 119 months median follow-up showed no significant difference between the two groups, with 467 deaths (19.9%) occurring in the exemestane group and 510 deaths (21.5%) in the tamoxifen group.

Table 8. Efficacy Results from the IES Study in Postmenopausal Women with Early Breast Cancer
ITT PopulationHazard Ratio
(95% CI)
p-value
(log-rank test)
Disease-free survival0.69 (0.58–0.82)0.00003
Time to contralateral breast cancer0.32 (0.15–0.72)0.00340
Distant recurrence-free survival0.74 (0.62–0.90)0.00207
Overall survival0.91 (0.81–1.04)0.16
ER and/or PgR positive
Disease-free survival0.65 (0.53–0.79)0.00001
Time to contralateral breast cancer0.22 (0.08–0.57)0.00069
Distant recurrence-free survival0.73 (0.59–0.90)0.00367
Overall survival0.89 (0.78–1.02)0.09065

Not adjusted for multiple testing.

Figure 1. Disease-Free Survival in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)
Figure 1 (Exemestane 02)

Figure 1 (Exemestane 02)

14.2 Treatment Of Advanced Breast Cancer

Exemestane 25 mg administered once daily was evaluated in a randomized double-blind, multicenter, multinational comparative study and in two multicenter single-arm studies of postmenopausal women with advanced breast cancer who had disease progression after treatment with tamoxifen for metastatic disease or as adjuvant therapy. Some patients also have received prior cytotoxic therapy, either as adjuvant treatment or for metastatic disease.

The primary purpose of the three studies was evaluation of objective response rate (complete response [CR] and partial response [PR]). Time to tumor progression and overall survival were also assessed in the comparative trial. Response rates were assessed based on World Health Organization (WHO) criteria, and in the comparative study, were submitted to an external review committee that was blinded to patient treatment. In the comparative study, 769 patients were randomized to receive exemestane tablets 25 mg once daily (N = 366) or megestrol acetate 40 mg four times daily (N = 403). Demographics and baseline characteristics are presented in Table 9.

Table 9. Demographics and Baseline Characteristics from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy
ParameterExemestane
(N = 366)
Megestrol Acetate
(N = 403)
Median Age (range)65 (35–89)65 (30–91)
ECOG Performance Status
  0167 (46%)187 (46%)
  1162 (44%)172 (43%)
  234 (9%)42 (10%)
Receptor Status
  ER and/or PgR +246 (67%)274 (68%)
  ER and PgR unknown116 (32%)128 (32%)
    Responders to prior tamoxifen68 (19%)85 (21%)
    NE for response to prior tamoxifen46 (13%)41 (10%)
Site of Metastasis
  Visceral ± other sites207 (57%)239 (59%)
  Bone only61 (17%)73 (18%)
  Soft tissue only54 (15%)51 (13%)
  Bone & soft tissue43 (12%)38 (9%)
Measurable Disease287 (78%)314 (78%)
Prior Tamoxifen Therapy
  Adjuvant or Neoadjuvant145 (40%)152 (38%)
  Advanced Disease, Outcome
    CR, PR, or SD ≥ 6 months179 (49%)210 (52%)
    SD < 6 months, PD or NE42 (12%)41 (10%)
Prior Chemotherapy
  For advanced disease ± adjuvant58 (16%)67 (17%)
  Adjuvant only104 (28%)108 (27%)
  No chemotherapy203 (56%)226 (56%)

The efficacy results from the comparative study are shown in Table 10. The objective response rates observed in the two treatment arms showed that exemestane was not different from megestrol acetate. Response rates for exemestane from the two single-arm trials were 23.4% and 28.1%.

Table 10. Efficacy Results from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy
Response CharacteristicsExemestane
(N=366)
Megestrol Acetate
(N=403)
Abbreviations: CR = complete response, PR = partial response, SD = stable disease (no change), TTP = time to tumor progression, C.I. = confidence interval, MA = megestrol acetate, EX = Exemestane
Objective Response Rate = CR + PR (%)15.012.4
  Difference in Response Rate (EX-MA)2.6
  95% C.I.7.5, -2.3
CR (%)2.21.2
PR (%)12.811.2
  SD ≥ 24 Weeks (%)21.321.1
Median Duration of Response (weeks)76.171.0
Median TTP (weeks)20.316.6
  Hazard Ratio (EX-MA)0.84

There were too few deaths occurring across treatment groups to draw conclusions on overall survival differences. The Kaplan-Meier curve for time to tumor progression in the comparative study is shown in Figure 2.

Figure 2. Time to Tumor Progression in the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy
Figure 2 (Exemestane 03)

Figure 2 (Exemestane 03)

16 How Supplied/Storage And Handling

Exemestane tablets, USP are a white to off-white, round, biconvex, bevel-edged, film-coated tablet engraved with 'US' on one face and plain on the other.

Exemestane tablets are packaged in HDPE bottles with a child-resistant screw cap.

Bottle of 30 tabletsNDC 0832-0595-30

Storage And Handling

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

17 Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Principal Display Panel - 25 Mg Tablet Bottle Label

NDC 0832-0595-30

Exemestane
Tablets, USP

25 mg

30 Tablets
Rx only

UPSHER-SMITH

Principal Display Panel (25 mg Tablet Bottle Label)

Principal Display Panel (25 mg Tablet Bottle Label)

* Please review the disclaimer below.